<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02167204</url>
  </required_header>
  <id_info>
    <org_study_id>7754</org_study_id>
    <secondary_id>NCI-2013-02162</secondary_id>
    <secondary_id>7754</secondary_id>
    <secondary_id>P01CA042045</secondary_id>
    <secondary_id>P30CA015704</secondary_id>
    <nct_id>NCT02167204</nct_id>
  </id_info>
  <brief_title>18F-FLT PET/CT in Measuring Cell Proliferation in Patients With Brain Tumors</brief_title>
  <official_title>Cellular Proliferation Imaging Using [18F] Fluorothymidine (FLT) Positron Emission Tomography (PET) in Brain Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot clinical trial studies fluorine F 18 fluorothymidine (FLT) positron emission
      tomography (PET)/computed tomography (CT) in measuring cell proliferation in patients with
      brain tumors. Comparing results of diagnostic procedures done before, during, and after
      treatment may help doctors measure tumor growth and plan the best treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Using FLT PET/CT as a measure of cellular proliferation, assess tissue proliferation in
      disease sites of brain tumor patients before therapy (surgery, chemotherapy or radiotherapy
      or any combination of these).

      II. Determine level of change in cellular proliferation compared with baseline (scan 1) in
      brain tumors at mid-therapy (scan 2), after completion of therapy (scan 3) and in the
      clinical follow-up period (scan 4), when possible.

      III. Correlate levels of cellular proliferation measured by FLT PET/CT at baseline and
      treatment-induced changes in brain tumor proliferation with clinical response status
      (clinical categories are complete remission, lesser degrees of response/stable disease, and
      no response).

      SECONDARY OBJECTIVES:

      I. Assess spatial heterogeneity of FLT uptake to identify local differences in brain tumor
      disease burden.

      OUTLINE:

      Patients undergo 18F-FLT PET/CT at baseline (pre-therapy), mid-therapy, completion of
      therapy, and 1 year after completion of therapy or time of suspected recurrence.

      After completion of study, patients are followed for up to 7 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">January 21, 2019</completion_date>
  <primary_completion_date type="Actual">January 21, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage Change in Measure of FLT Flux</measure>
    <time_frame>Baseline to up to 1 year after completion of treatment</time_frame>
    <description>The percentage change in the kinetic model parameter of FLT flux (Ki) was recorded. Ki is estimated from parameters derived by fitting the FLT input function and the total blood activity curve to the tissue time-activity curve data.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage Change in Measure of Reflecting Transport</measure>
    <time_frame>Baseline to up to 1 year after completion of treatment</time_frame>
    <description>The percentage change in the kinetic model parameter of FLT transport (K1) was recorded. K1 is defined as the transfer of FLT from blood into tissue (tumor).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage Change in Measure of Standard Uptake Value</measure>
    <time_frame>Baseline to up to 1 year after completion of treatment</time_frame>
    <description>The percentage change in the maximum standard uptake value (SUVmax) was recorded. SUVmax is defined as the amount of FLT uptake in a lesion.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>Up to 7 years</time_frame>
    <description>Time from study entry to death will be recorded</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Response Assessed Using Revised Assessment in Neuro-Oncology Criteria</measure>
    <time_frame>Up to 7 years</time_frame>
    <description>This is clinical response as assessed at physician discretion using standard of care criteria.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Metastatic Malignant Neoplasm in the Brain</condition>
  <condition>Primary Brain Neoplasm</condition>
  <condition>Recurrent Brain Neoplasm</condition>
  <arm_group>
    <arm_group_label>Diagnostic (18F-FLT PET/CT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo 18F-FLT PET/CT at baseline (pre-therapy), mid-therapy, completion of therapy, and 1 year after completion of therapy or time of suspected recurrence.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Computed Tomography</intervention_name>
    <description>Undergo 18F-FLT PET/CT</description>
    <arm_group_label>Diagnostic (18F-FLT PET/CT)</arm_group_label>
    <other_name>CAT</other_name>
    <other_name>CAT Scan</other_name>
    <other_name>Computerized Axial Tomography</other_name>
    <other_name>Computerized Tomography</other_name>
    <other_name>CT</other_name>
    <other_name>CT SCAN</other_name>
    <other_name>tomography</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Fluorothymidine F-18</intervention_name>
    <description>Undergo 18F-FLT PET/CT</description>
    <arm_group_label>Diagnostic (18F-FLT PET/CT)</arm_group_label>
    <other_name>18F-FLT</other_name>
    <other_name>3'-Deoxy-3'-(18F) Fluorothymidine</other_name>
    <other_name>3'-deoxy-3'-[18F]fluorothymidine</other_name>
    <other_name>Fluorothymidine F 18</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Positron Emission Tomography</intervention_name>
    <description>Undergo 18F-FLT PET/CT</description>
    <arm_group_label>Diagnostic (18F-FLT PET/CT)</arm_group_label>
    <other_name>Medical Imaging, Positron Emission Tomography</other_name>
    <other_name>PET</other_name>
    <other_name>PET SCAN</other_name>
    <other_name>Positron Emission Tomography Scan</other_name>
    <other_name>Positron-Emission Tomography</other_name>
    <other_name>proton magnetic resonance spectroscopic imaging</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have a diagnosis or suspected diagnoses of brain tumor (primary, recurrent, or
             metastatic) by standard clinical diagnosis such as pathology or imaging

          -  Planned for treatment with radiation, chemotherapy and surgical resection or any of
             these treatment strategies combined

        Exclusion Criteria:

          -  Inability to provide informed consent

          -  Pregnancy

          -  Inability to lie still for the imaging study

          -  Weight over 350 lbs.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jason Rockhill</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>June 16, 2014</study_first_submitted>
  <study_first_submitted_qc>June 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 18, 2014</study_first_posted>
  <results_first_submitted>October 28, 2019</results_first_submitted>
  <results_first_submitted_qc>January 8, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 13, 2020</results_first_posted>
  <last_update_submitted>January 8, 2020</last_update_submitted>
  <last_update_submitted_qc>January 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alovudine</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 26, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/04/NCT02167204/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Diagnostic (18F-FLT PET/CT)</title>
          <description>Patients undergo 18F-FLT PET/CT at baseline (pre-therapy), mid-therapy, completion of therapy, and 1 year after completion of therapy or time of suspected recurrence.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Diagnostic (18F-FLT PET/CT)</title>
          <description>Patients undergo 18F-FLT PET/CT at baseline (pre-therapy), mid-therapy, completion of therapy, and 1 year after completion of therapy or time of suspected recurrence.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.5" lower_limit="34.8" upper_limit="69.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage Change in Measure of FLT Flux</title>
        <description>The percentage change in the kinetic model parameter of FLT flux (Ki) was recorded. Ki is estimated from parameters derived by fitting the FLT input function and the total blood activity curve to the tissue time-activity curve data.</description>
        <time_frame>Baseline to up to 1 year after completion of treatment</time_frame>
        <population>4 patients had 2 scans, 2 patients had 3 scans</population>
        <group_list>
          <group group_id="O1">
            <title>2 Diagnostic (18F-FLT PET/CT)Scans</title>
            <description>Patients completing two 18F-FLT PET/CT scans - at baseline (pre-therapy) and mid-therapy</description>
          </group>
          <group group_id="O2">
            <title>2 or 3 Diagnostic (18F-FLT PET/CT) Scans</title>
            <description>Patients completing two or three 18F-FLT PET/CT scans - at baseline (pre-therapy) and mid-therapy and completion of therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change in Measure of FLT Flux</title>
          <description>The percentage change in the kinetic model parameter of FLT flux (Ki) was recorded. Ki is estimated from parameters derived by fitting the FLT input function and the total blood activity curve to the tissue time-activity curve data.</description>
          <population>4 patients had 2 scans, 2 patients had 3 scans</population>
          <units>percent change</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4" lower_limit="-48" upper_limit="33"/>
                    <measurement group_id="O2" value="3" lower_limit="-48" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage Change in Measure of Reflecting Transport</title>
        <description>The percentage change in the kinetic model parameter of FLT transport (K1) was recorded. K1 is defined as the transfer of FLT from blood into tissue (tumor).</description>
        <time_frame>Baseline to up to 1 year after completion of treatment</time_frame>
        <population>4 patients had 2 scans and 2 had 3 scans.</population>
        <group_list>
          <group group_id="O1">
            <title>2 Diagnostic (18F-FLT PET/CT) Scans</title>
            <description>Patients completing two 18F-FLT PET/CT scans - at baseline (pre-therapy) and mid-therapy</description>
          </group>
          <group group_id="O2">
            <title>2 or 3 Diagnostic (18F-FLT PET/CT) Scans</title>
            <description>Patients completing three 18F-FLT PET/CT scans - at baseline (pre-therapy) and mid-therapy and completion of therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change in Measure of Reflecting Transport</title>
          <description>The percentage change in the kinetic model parameter of FLT transport (K1) was recorded. K1 is defined as the transfer of FLT from blood into tissue (tumor).</description>
          <population>4 patients had 2 scans and 2 had 3 scans.</population>
          <units>percent change</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11" lower_limit="-44" upper_limit="130"/>
                    <measurement group_id="O2" value="-11" lower_limit="-44" upper_limit="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage Change in Measure of Standard Uptake Value</title>
        <description>The percentage change in the maximum standard uptake value (SUVmax) was recorded. SUVmax is defined as the amount of FLT uptake in a lesion.</description>
        <time_frame>Baseline to up to 1 year after completion of treatment</time_frame>
        <population>4 patients had 2 scans, 2 patients had 3 scans</population>
        <group_list>
          <group group_id="O1">
            <title>2 Diagnostic (18F-FLT PET/CT) Scans</title>
            <description>Patients undergo two 18F-FLT PET/CT at baseline (pre-therapy) and mid-therapy</description>
          </group>
          <group group_id="O2">
            <title>2 or 3 Diagnostic (18F-FLT PET/CT) Scans</title>
            <description>Patients undergo three 18F-FLT PET/CT at baseline (pre-therapy), mid-therapy and completion of therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change in Measure of Standard Uptake Value</title>
          <description>The percentage change in the maximum standard uptake value (SUVmax) was recorded. SUVmax is defined as the amount of FLT uptake in a lesion.</description>
          <population>4 patients had 2 scans, 2 patients had 3 scans</population>
          <units>percent change</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14" lower_limit="-74" upper_limit="20"/>
                    <measurement group_id="O2" value="-10" lower_limit="-74" upper_limit="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Survival</title>
        <description>Time from study entry to death will be recorded</description>
        <time_frame>Up to 7 years</time_frame>
        <population>All patients with at least one 18F-FLT/CT study</population>
        <group_list>
          <group group_id="O1">
            <title>Diagnostic (18F-FLT PET/CT)</title>
            <description>Patients undergo 18F-FLT PET/CT at baseline (pre-therapy), mid-therapy, completion of therapy, and 1 year after completion of therapy or time of suspected recurrence.</description>
          </group>
        </group_list>
        <measure>
          <title>Survival</title>
          <description>Time from study entry to death will be recorded</description>
          <population>All patients with at least one 18F-FLT/CT study</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.2" lower_limit="5.4" upper_limit="200.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinical Response Assessed Using Revised Assessment in Neuro-Oncology Criteria</title>
        <description>This is clinical response as assessed at physician discretion using standard of care criteria.</description>
        <time_frame>Up to 7 years</time_frame>
        <population>Data not collected for this Outcome Measure</population>
        <group_list>
          <group group_id="O1">
            <title>Diagnostic (18F-FLT PET/CT)</title>
            <description>Patients undergo 18F-FLT PET/CT at baseline (pre-therapy), mid-therapy, completion of therapy, and 1 year after completion of therapy or time of suspected recurrence.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Response Assessed Using Revised Assessment in Neuro-Oncology Criteria</title>
          <description>This is clinical response as assessed at physician discretion using standard of care criteria.</description>
          <population>Data not collected for this Outcome Measure</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 hours after injection of 18F-FLT</time_frame>
      <desc>This is an imaging study. No adverse events are expected or have been reported due to tracer injection or imaging during the 24 hour monitoring period. All deaths were due to the natural course of cancer after the time period that adverse events were collected for this study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Diagnostic (18F-FLT PET/CT)</title>
          <description>Patients undergo 18F-FLT PET/CT at baseline (pre-therapy), mid-therapy, completion of therapy, and 1 year after completion of therapy or time of suspected recurrence.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Hannah Linden</name_or_title>
      <organization>University of Washington</organization>
      <phone>206-606-2053</phone>
      <email>hmlinden@uw.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

